Master pharmaceutical products registration in the Levant

Master pharmaceutical products registration in the Levant udemy course

Master pharmaceutical products registration in Lebanon - Syria

Master pharmaceutical products registration in the levant, the part of the world driven by Jordan from a regulatory point of view, as both Lebanon and Syria are following the JFDA of Jordan for the regulation of both medical devices and pharmaceutical products, and consequently JFDA is following SFDA of Saudi Arabia.

What will you Learn?

• Pharmaceutical products registration documentation- process in Lebanon

• Pharmaceutical products registration documentation- process in Syria

• Products importation to Lebanon

• Products importation to Syria

• Fast track products approvals

• Special approvals for specific categories of products

• Prodcuts pricing in both countries 

• Stay tuned with the recent updates

  
  

Lebanon

The Ministry of Public Health (MOPH) oversees the registration of all pharmaceutical products, encompassing both locally manufactured and imported drugs. The Drug Registration Technical Committee (TC) within the MOPH meticulously reviews each application to ensure compliance with national standards. Engaging with local regulatory consultants can facilitate understanding and adherence to these requirements.

Syria

The Ministry of Health (MoH) is responsible for the registration of pharmaceutical products in Syria. All foreign pharmaceutical firms and their products must be registered with the MoH before they can be marketed in the country. Distribution agreements between international pharmaceutical companies and local agents are regulated by the General Foreign Trade Organization.

The US Arab Chamber of Commerce offers services to assist pharmaceutical companies in legalizing their Certificates of Pharmaceutical Products for Syria. These services include document review and certification, embassy liaison, legal consultation, and notarization services.

Recent updates within the Lebanese Ministry of Public Health, influenced by prior implementations within the Gulf Cooperation Council (GCC), represent a crucial area of focus. These updates necessitate continuous monitoring and adaptation to ensure regulatory compliance and facilitate the successful placement of pharmaceutical products within the Lebanese market. In conclusion, while sharing a foundation rooted in the JFDA, the regulatory environments of Lebanon and Syria possess unique characteristics requiring a tailored approach to pharmaceutical product registration.

Let's take-off

See you onboard